FDA: Dental Composite Resin Devices – Premarket Notification (510(k)) Submissions

Product scope is unchanged (21 CFR 872.3690/EBF and 21 CFR 872.3765/EBC, same excluded resin categories), but nearly everything else has been restructured, expanded, or updated.

1. Overall Structure

• The 2026 guidance drops the detailed "Abbreviated 510(k)" submission-format content (coversheet, summary report structure, declaration of conformity mechanics) that made up a large portion of the 2005 document. It instead points submitters to the separate "Electronic Submission Template for Medical Device 510(k) Submissions" guidance.
• The 2026 version adds a wholly new "Modifications" section (Section IV), addressing when a device change triggers a new 510(k) under 21 CFR 807.81(a)(3), and introduces Predetermined Change Control Plans (PCCPs) under new FD&C Act Section 515C (added by the 2022 FDORA law) — a mechanism that didn't exist in 2005.
• Non-clinical testing is reorganized from a single combined section into five distinct subsections, each with its own "Significance" and "Recommendation" framing: Material Characterization, Physical and Mechanical Properties, Energy for Curing Photoinitiated Resins, Working/Setting Times for Self-Curing Resins, and Radiopacity.
• A new "Guidance History" table is appended, tracking prior versions (1998, 2005, 2024 draft, 2026 final).

2. New Requirement: Shelf Life (Section D — entirely new)

• The 2005 guidance had no shelf-life testing section at all.
• The 2026 guidance now expects submitters to:
• Repeat mechanical/performance bench tests on aged samples to confirm the device performs through its proposed expiration date.
• Use accelerated aging per the currently FDA-recognized version of ASTM F1980, with a rationale connecting accelerated results to real-time behavior.
• Because these are polymeric materials, run real-time aging studies in parallel with 510(k) review, with results kept in design/development files under ISO 13485:2016 Clause 7.3.10 (full reports don't need to be submitted to FDA).
• This ties to a broader regulatory change: FDA's Quality System Regulation (21 CFR Part 820) was amended effective February 2, 2026 to incorporate ISO 13485:2016 by reference — a change industry needs to be aware of independent of this guidance.

3. Device Description — More Prescriptive

• 2026 explicitly requires:
• A description of curing chemistry and any substances that may be eluted from the device.
• Complete chemical composition by percent mass, summing to 100%, for *every* formulation marketed.
• Identification of the 510(k) clearance status of any packaged accessory devices, if applicable.
• 2005's device description requirement was comparably brief (principle of operation, marketing/accessories description).

4. Predicate Comparison Table — Expanded Parameters

• 2005's comparison table covered four broad categories: intended use, composition, physical properties, and FDA-recognized standards followed.
• 2026's sample table itemizes specific comparative endpoints: principle of operation, mechanism of action, patient-contacting material composition, compressive strength, flexural strength, depth of cure, hardness, water absorption, water solubility, and "other relevant characteristics" — with an explicit note that this list is not exhaustive.

5. Biocompatibility — Explicit Endpoint List

• 2005 pointed to ISO 7405:1997 generically and allowed reliance on predicate/literature without listing required endpoints.
• 2026 specifies the exact endpoints expected in the biocompatibility evaluation: cytotoxicity, sensitization, irritation/intracutaneous reactivity, acute systemic toxicity, subacute/subchronic toxicity, and genotoxicity, framed within the current ISO 10993-1 risk-management approach (per FDA's ISO 10993-1 guidance) rather than ISO 7405 alone.
• 2026 also explicitly classifies these devices as "external communicating devices" with permanent tissue/bone/dentin contact — a specific classification not stated this way in 2005.
• 2026 adds a pointer to using a Master Access File (MAF) Letter of Authorization as an acceptable biocompatibility data source.

6. Physical/Mechanical Testing — More Recognized Standards, New Categorization

• 2005 referenced a single standard: ISO 4049:2000(E).
• 2026 references three standards: ISO 4049 (restoratives), ISO 6874 (pit and fissure sealants — new), and ISO 9917-2 (resin-modified cements — new), reflecting the broader EBC/EBF product scope.
• 2026 splits required tests into two tiers:
• Strength/water-insolubility set: flexural strength, water absorption, water solubility.
• Additional strength/stiffness/hardness set: compressive strength, elastic modulus, surface hardness.
• 2026 adds a new specific requirement: if a device is marketed as "hybrid" or "nanofilled," the submission must include filler particle size distribution, since particle size affects performance and esthetics — 2005 listed particle size as a generic physical property without this marketing-claim trigger.

7. Curing Energy / Working-Setting Time Sections

• Largely consistent with 2005, but 2026 adds specificity: testing should be performed on a "representative or universal shade" unless otherwise specified, and depth-of-cure testing is tied to "normal mode at 10 seconds."
• Ion-release protocol (fluoride, calcium, phosphorus, nitrate) is retained from 2005 but 2026 adds the instruction that water must be replaced daily during the 7-day release study.

8. Clinical Performance Testing — Substantially Rewritten

• 2005 emphasized animal testing recommendations (skeletally mature animal model, predicate as positive control, radiographic/histologic assessment). This animal-testing guidance is removed entirely in 2026.
• 2026 instead adds substantial new content on:
• Real-World Data/Evidence (RWD/RWE) as potential support for enhanced clinical outcome claims on already-cleared devices, and when an IDE would or wouldn't be triggered.
• Acceptance of ex-US clinical data under 21 CFR 812.28.
• Encouragement to use the Q-Submission (pre-submission) program to discuss clinical protocols with FDA before conducting studies.
• Both versions agree clinical data is generally unnecessary but may be requested for novel claims (e.g., remineralization, reduced decay, other therapeutic benefit claims).

9. Labeling

• Content is largely consistent (compressive strength, flexural strength, light intensity, wavelength, depth of cure, working/curing/setting times), but 2026 explicitly adds radiopacity (mm of aluminum) to the recommended labeling list, which 2005 did not include in its labeling section (only in the physical-properties test list).

10. Administrative/Contact Changes

• Reviewing office has changed: 2005 routed questions to the Dental Devices Branch, Division of Anesthesiology, Infection Control, General Hospital, and Dental Devices; 2026 routes to OHT1 (Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices) / DHT1B (Division of Dental and ENT Devices) — reflecting FDA's internal reorganization.
• 2026 assigns a formal guidance document number (GUI00016050) and docket number (FDA-2024-D-2511) for comment tracking, consistent with FDA's current guidance-document practices.

The differences are generated by AI models and can contain mistakes. Please double-check the content.